Protalix BioTherapeutics, Inc.
PLX
$2.22
-$0.14-5.93%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -79.38% | 432.79% | -333.72% | 1,335.98% | 104.53% |
| Total Depreciation and Amortization | 0.50% | 4.39% | 4.03% | 3.33% | 4.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.42% | -44.13% | 102.51% | -40.72% | 1,976.36% |
| Change in Net Operating Assets | -713.04% | -56.06% | 180.94% | -3.44% | -274.95% |
| Cash from Operations | -147.22% | 984.98% | 154.39% | 28.68% | -3.46% |
| Capital Expenditure | 22.08% | -88.83% | 19.08% | -15.55% | -40.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -161.04% | 802.96% | -11,716.67% | 14.29% | -16.67% |
| Cash from Investing | -186.08% | 479.77% | -120.63% | -15.07% | -40.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 2.74% | -- | -100.00% | -19.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 2.74% | -- | -100.00% | -19.15% |
| Foreign Exchange rate Adjustments | 689.61% | -148.39% | -158.33% | -400.00% | 150.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -151.60% | 2,448.02% | 124.32% | -171.79% | -417.55% |